GlassScriptPhysician profile
Shaneika Mckenzie
NPI 1083226013
$4,853.39
in general payments reported to CMS, 2019-2025
34 companies · $1,604 in 2025
The $1,604 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $866 · 2024: $2,383 · 2025: $1,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,853.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $679.60 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $666.42 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $634.05 | 2023-2025 | Jardiance |
| Pfizer INC. | $468.88 | 2023-2025 | |
| Abbvie INC. | $391.26 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $247.82 | 2024 | Camzyos |
| Amgen INC. | $210.93 | 2023-2025 | Otezla, Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $196.98 | 2023-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.15 | 2023-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $113.75 | 2025 | |
| Lilly USA, LLC | $101.84 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Ironwood Pharmaceuticals, INC | $93.57 | 2023-2024 | Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.45 | 2025 | Caplyta |
| Bridgebio Pharma, INC. | $86.13 | 2025 | Attruby |
| Corcept Therapeutics | $72.73 | 2025 | Korlym |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $67.00 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $62.99 | 2024-2025 | Onpattro |
| Merck Sharp & Dohme LLC | $56.09 | 2023-2025 | Verquvo, Belsomra, Steglatro |
| Ardelyx, INC. | $55.61 | 2024 | Ibsrela |
| Glaxosmithkline, LLC. | $53.98 | 2025 | Shingrix, Arexvy, Fluarix Quadrivalent |
| Lundbeck LLC | $53.58 | 2025 | Rexulti |
| Medtronic, INC. | $41.40 | 2024 | Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $36.68 | 2024 | |
| Scilex Pharmaceuticals INC. | $35.21 | 2023 | Ztlido |
| Inspire Medical Systems, INC. | $33.17 | 2025 | Inspire |
| Scpharmaceuticals INC. | $33.14 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $27.97 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $27.72 | 2024 | Arcalyst |
| Intra-Sana Laboratories | $17.83 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Kiniksa Pharmaceuticals, LTD. | $16.64 | 2023 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.62 | 2024 | Lifevest |
| Currax Pharmaceuticals LLC | $13.90 | 2024 | Contrave |
| Dexcom, INC. | $13.27 | 2024 | Dexcom G6 Transmitter |
| Cvrx, INC. | $11.03 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaneika Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.